- Results from second in vivo study of 2018 a success
- DehydraTECH™ had a 90.2 percent greater absorption rate in the first 10 minutes
- Clients are improving high-quality products through the enhancement of this drug delivery platform
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a company focused on developing and out-licensing its disruptive drug delivery platform DehydraTECH™, recently announced the results of its second in vivo study of 2018 evaluating this edible technology’s use as a nicotine delivery system (http://cnw.fm/Jm6IN).
The study was carried out by a third-party laboratory, which discovered that the absorption of nicotine was significantly greater when delivered by DehydraTECH™. In comparison with the tested control, the DehydraTECH™ system delivered a 90.2 percent greater absorption rate in the first 10 minutes. Because smoking gets the drug into the body so quickly, the speed of absorption for this edible form of nicotine delivery is very important in the overall success of providing a smoking alternative.
Lexaria’s DehydraTECH™ drug delivery platform offers a solution to the high numbers of smoking-related deaths and diseases. According to the U.S. Centers for Disease Control and Prevention (CDC), six million people die every year worldwide as a result of smoking, and 30 times that are living with serious illnesses related to a history of smoking (http://cnw.fm/zxTF6).
This disruptive drug delivery platform has multiple uses. Lexaria out-licenses DehydraTECH™ to entities whose goal is to deliver healthier ingestion methods of cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. With eight patents and nearly 50 more pending worldwide, Lexaria is enhancing the high-quality products of clients, not competing with them. Clients are improving upon high-quality products by increasing absorption rates, as well as improving taste and smell of the final product.
Clients are utilizing this edible technology in chocolates, beverages, dissolvable infusion products and more. Eighty percent of the company’s total revenue in 2018 is anticipated to come from the licensing of DehydraTECH™, with a number of licensing agreements currently in the works through its four wholly owned subsidiaries serving the nicotine, hemp, pharmaceutical and cannabis industries.
For more information, visit the company’s website at www.LexariaBioscience.com
More from CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.cannabisnewswire.com